T he number of patients with end-stage renal disease requiring hemodialysis has been gradually increasing. In 2012, more than 400 000 American patients with end-stage renal disease were on hemodialysis, including over 98 000 new patients. 1 In Japan, more than 300 000 patients with end-stage renal disease are on hemodialysis, and the candidate pool increases by over 30 000 patients per year. 2 Dialysis patients are associated with a higher risk for the development of cardiovascular diseases with calcified degeneration of cardiac valves and/or heavy calcification of coronary arteries. [3] [4] [5] [6] Calcified aortic stenosis (AS) is particularly common in hemodialysis patients, and has been found to be an independent risk factor for death in hemodialysis patients. 6, 7 Regarding the clinical outcomes of hemodialysis patients with severe AS, there are only a few small studies suggesting the higher mortality and morbidity rates following surgical aortic valve replacement (AVR). [8] [9] [10] However, the characteristics and prognosis of hemodialysis patients with severe AS have not yet been well defined in comparison with those in nonhemodialysis patients with severe AS. Also, it is not clear whether the effect size of the initial AVR strategy relative to the conservative strategy differs between hemodialysis patients and nonhemodialysis patients, although we previously reported that the initial AVR strategy was associated with markedly lower mortality risk than the conservative strategy in the asymptomatic patients with severe AS. 11 Therefore, we sought to investigate the longterm outcomes of hemodialysis patients with severe AS and to evaluate the effect of the initial AVR strategy relative to the conservative strategy in clinical outcomes compared between hemodialysis and nonhemodialysis patients in a large Japanese observational database of consecutive patients with severe AS.
Methods Study Design and Patient Population
The study design of the CURRENT AS (contemporary outcomes after surgery and medical treatment in patients with severe aortic stenosis) registry was previously described in detail. 11 In brief, the CURRENT AS registry is a retrospective, multicenter registry that enrolled 3815 consecutive patients with severe AS from 27 centers (Appendix S1, on-site surgical facility in 20 centers) in Japan between January 2003 and December 2011. We examined the hospital database of transthoracic echocardiography and enrolled consecutive patients meeting the definition of severe AS (peak aortic jet velocity >4.0 m/s, mean aortic pressure gradient >40 mm Hg, or aortic valve area <1.0 cm 2 ) for the first time during the study period. We excluded patients with a history of aortic valve repair/ replacement/plasty or percutaneous aortic balloon valvuloplasty. The institutional review boards in all 27 participating centers approved the protocol. Written informed consent from each patient was waived because clinical information was obtained from the routine practice, and no patient refused to participate in the study when contacted for follow-up. Among the 3815 study patients, there were 405 hemodialysis patients (initial AVR group: N=135 [33.3%], and conservative group: N=270) and 3410 nonhemodialysis patients (initial AVR group: N=1062 [31.1%], and conservative group: N=2348) at the time of the index echocardiography (Figure 1) . The conservative group consisted of all the patients other than those in whom AVR was planned based on the index echocardiographic findings. 
Clinical Perspective
What Is New?
• Although the initial aortic valve replacement strategy improves prognosis of hemodialysis patients with severe aortic stenosis, the magnitude of its benefit is smaller in hemodialysis patients than in nonhemodialysis patients, which could at least in part be explained by the extremely high rate of aortic valve procedure-related death in hemodialysis patients.
What Are the Clinical Implications?
• The initial aortic valve replacement is an effective procedure to treat hemodialysis patients with severe aortic stenosis, but there is an urgent unmet need to improve the procedural outcomes of aortic valve replacement in hemodialysis patients.
management included watchful waiting for symptoms in asymptomatic patients, and medical management of angina and/or heart failure in symptomatic patients. There were 3 main reasons why AVR was not performed in the conservative group. First, patients were considered to have no formal AVR indications by their attending physician (1388 patients, 53.0%) either because of absence of symptoms (1067 patients) or improvement of symptoms by medication (237 patients). Second, patients had unacceptably high surgical risk (798 patients, 30.5%). Third, patients refused to undergo AVR (403 patients, 15.4%).
The effect of the initial AVR strategy relative to the conservative strategy was assessed based on the initial strategies regardless of the actual performance of AVR. The follow-up was commenced on the day of the index echocardiography except for the analysis comparing the clinical outcomes after AVR between hemodialysis and nonhemodialysis patients, in which the follow-up was commenced on the day of AVR.
Echocardiography
All patients underwent a comprehensive 2-dimensional and Doppler echocardiographic evaluation in each participating center. Peak aortic jet velocity and mean pressure gradient were obtained with the use of the simplified Bernoulli equation. Aortic valve area was calculated with the use of the standard continuity equation and was indexed by body surface area. 12 
Data Collections and Definitions
Baseline clinical information was collected by reviewing the hospital charts or database. Follow-up information was collected mainly by reviewing the hospital charts, and additional information was collected through contact with patients, their families, and/or referring physicians by sending mails regarding survival status, symptoms, and subsequent hospitalizations.
The primary outcome measure in the present analysis was all-cause death. The secondary outcome measures included cardiovascular death, aortic valve-related death, aortic valve procedure-related death, sudden death, noncardiovascular death, hospitalization for heart failure (HF), and a composite of aortic valve-related death or hospitalization for HF. The causes of death were classified according to the Valve Academic Research Consortium definitions and were adjudicated by a clinical event committee (Data S1). 13, 14 Aortic valve-related death included aortic valve procedure-related death, sudden death, and death attributable to HF possibly related to the aortic valve. Hospitalization for HF was defined as hospitalization because of worsening HF requiring intravenous drug therapy.
Statistical Analysis
Categorical variables are presented as numbers and percentages and were compared with the v 2 test or Fisher exact test.
Continuous variables are presented as the mean and SD or median and interquartile range. Continuous variables were compared using Student t test or Wilcoxon rank sum test based on their distributions. The Kaplan-Meier method was used to calculate the cumulative incidence of events, and the differences were assessed with the log-rank test. The Cox proportional hazard models were used to estimate the adjusted risk of hemodialysis patients relative to nonhemodialysis patients or the adjusted risk of initial AVR strategy relative to conservative strategy for all-cause death, cardiovascular death, aortic valve-related death, aortic valve procedurerelated death, sudden death, noncardiovascular death, hospitalization for HF, and a composite of aortic valve-related death and hospitalization for HF. We selected 20 clinically relevant factors listed in Table 1 and Tables S1 and S2 as the risk-adjusting variables consistent with the previous report. We constructed parsimonious models with a limited number of variables for aortic valve procedure-related death, because the number of patients with this event was too small for the nonparsimonious model. We selected 6 clinically relevant variables as the risk-adjusted variables as listed in Table 1 and  Tables S1 and S2 in the parsimonious models. The centers were incorporated into all the models as the stratification variable. With the exception of age, the continuous variables were dichotomized by the median values or clinically meaningful reference values. Because the differences in the age distributions between the hemodialysis and nonhemodialysis groups and between the initial AVR and conservative strategies were too large to allow the dichotomous approach, we treated age as a continuous variable in the Cox proportional hazard models. The risks for the clinical end points were expressed as hazard ratios and their 95% CI. We also evaluated the interaction between hemodialysis/nonhemodialysis subgroups and the effect of the initial AVR strategy relative to the conservative strategy for the primary and secondary outcome measures.
All statistical analyses were conducted by 2 physicians (Y.K. and T.T.) and a statistician (T.M.) with the use of JMP 10.0.2 or SAS 9.4. All reported P values were 2-tailed, and P<0.05 was considered statistically significant.
Results

Baseline Characteristics and Clinical Outcomes: Hemodialysis Versus Nonhemodialysis Patients
Baseline characteristics were significantly different between hemodialysis patients and nonhemodialysis patients (Table 1) . Values are number (%), meanAESD, or median (interquartile range) unless otherwise stated. AVR indicates aortic valve replacement; PROM, predicted risk of mortality; STS, Society of Thoracic Surgeons. *Potential independent variables selected in the Cox proportional hazard models for all-cause death, cardiovascular death, aortic valve-related death, sudden death, noncardiovascular death, hospitalization for heart failure, and a composite of aortic valve-related death or hospitalization for heart failure.
The median follow-up period after the index echocardiography was 1361 (interquartile range: 1055-1697) days, with a 90% follow-up rate at 2 years. Cumulative 5-year incidence of the first surgical AVR or transcatheter aortic valve implantation (TAVI) was significantly higher in hemodialysis patients than in nonhemodialysis patients in the entire study population as well as in the conservatively managed population (Figure 2 and Figure S1 ). TAVI was performed in 40 patients including 1 hemodialysis patient during the follow-up period.
Cumulative 5-year incidence of the primary outcome measure (all-cause death) was significantly higher in hemodialysis patients than in nonhemodialysis patients (71% versus 40%, P<0.001) with a notably higher rate in the first year (35.9% versus 13.4%) after the index echocardiography (Table 2 and Figure 3 ). The risk for sudden death was markedly higher in hemodialysis patients than in nonhemodialysis patients (Table 2 and Figure 3 ). Cumulative 5-year incidence of hospitalization for HF was not significantly different between hemodialysis and nonhemodialysis patients ( Table 3 ). The results from the adjusted analysis were fully consistent with those from the unadjusted analysis (Table 3) .
Baseline Characteristics and Clinical Outcomes in Hemodialysis and Nonhemodialysis Patients: Initial AVR Versus Conservative Strategies
The differences in baseline characteristics between the initial AVR and conservative groups were basically consistent in both hemodialysis and nonhemodialysis patients. Surgical risk scores were significantly lower in the initial AVR group than in the conservative group. Patients in the initial AVR group had greater echocardiographic AS severity and left ventricular wall thickness than those in the conservative group (Table 3,  Table S1 ).
In both hemodialysis and nonhemodialysis patients, cumulative 5-year incidence of all-cause death was significantly lower in the initial AVR group than in the conservative group (Table 4 and Figure 4) . However, the effect size of the initial AVR strategy relative to the conservative strategy on mortality was smaller in hemodialysis patients than in nonhemodialysis patients (adjusted hazard ratio 0.62, 95% CI 0.43-0.90, P=0.01, and adjusted hazard ratio 0.40, 95% CI 0.33-0.48, P<0.001, P interaction=0.001) ( Table 4 ). In both hemodialysis and nonhemodialysis patients, the lower risks of the initial AVR group relative to the conservative group were highly significant for sudden death and HF hospitalization (Table 4 and Figure 4 ). In addition, we have conducted a propensityscore matched analysis as a sensitivity analysis and analyzed the initial AVR versus conservative groups in hemodialysis and nonhemodialysis patients, respectively. The results of Number of patients with at least 1 event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5 years. Follow-up was commenced on the day of the index echocardiography. HR indicates hazard ratio. Values are number (%), meanAESD, or median (interquartile range) unless otherwise stated. AVR indicates aortic valve replacement; PROM, predicted risk of mortality; STS, Society of Thoracic Surgeons. *Potential independent variables selected in the Cox proportional hazard models for all-cause death, cardiovascular death, and a composite of aortic valve-related death or hospitalization for heart failure. † Potential independent variables selected in the Cox proportional hazard models for aortic valve-related death, aortic valve-procedure death, sudden death, noncardiovascular death, and hospitalization for heart failure.
sensitivity analysis were similar to those of the primary analysis (Tables S3 through S6 and Figures S2 and S3) .
Baseline Characteristics and Clinical Outcomes After AVR: Hemodialysis Versus Nonhemodialysis Patients
Among the 135 hemodialysis and 1062 nonhemodialysis patients in the initial AVR group, surgical AVR or TAVI was actually performed in 131 patients (97%) and 1043 patients (98%), respectively. TAVI was performed only in 11 nonhemodialysis patients. The differences in baseline clinical and echocardiographic characteristics between hemodialysis and nonhemodialysis patients in the initial AVR group were consistent with those in the entire study population (Table S2 ). The procedural characteristics in 1174 patients who actually underwent AVR based on the initial treatment strategy are presented in Table S3 . Hemodialysis patients Years after diagnosis more often underwent AVR combined with coronary artery bypass grafting and less often AVR combined with replacement of ascending aorta than nonhemodialysis patients. A bioprosthetic valve was less often used in hemodialysis patients than in nonhemodialysis patients (Table S7) . Hemodialysis patients were associated with markedly higher risk for all-cause death and aortic valve procedure-related death after AVR than nonhemodialysis patients (Table 5, Figure 5 ). The 30-day mortality rate after AVR was 7.6% in hemodialysis patients, which was markedly higher than 1.3% in nonhemodialysis patients ( Figure 5 ). The rate of aortic valve procedure-related death, which predominantly occurred within 6 months of the AVR procedure, was markedly higher in the hemodialysis patients than in the nonhemodialysis patients (21.2% and 2.3%, P<0.001) ( Table 5 and Figure 5 ). In hemodialysis patients, the cumulative 5-year incidences of all-cause death and hospitalization for HF were not significantly different between the bioprosthetic and mechanical valves ( Figure S4 ). Only 2 patients underwent redo AVR in the 80 hemodialysis patients who received the bioprosthetic valve.
Discussion
The main findings of the present study are as follows: (1) Hemodialysis patients with severe AS have a significantly poorer prognosis than nonhemodialysis patients with severe AS; (2) The initial AVR strategy as compared with the conservative strategy in hemodialysis patients was associated with significantly lower long-term mortality risk, particularly the risk for sudden death; (3) However, the AVR procedurerelated mortality was much higher in hemodialysis patients than that in nonhemodialysis patients.
Previous small studies have suggested the poor prognosis after AVR in hemodialysis patients with severe AS. [6] [7] [8] [9] [10] The present study including a large number of hemodialysis patients with severe AS clearly demonstrated that hemodialysis patients had a significantly higher 5-year cumulative mortality rate than nonhemodialysis patients (71% versus 40%) with a notably higher rate in the first year (35.9% versus 13.4%), although AVR was more often performed in hemodialysis patients than in nonhemodialysis patients. Compared with the survival rates of 89.7% at 1 year and 60.5% at 5 years after hemodialysis introduction reported from the Society for Dialysis Therapy, the mortality rate of our study is considerably higher, suggesting the grimmer prognosis of hemodialysis patients with severe AS, although the durations after the hemodialysis introduction were variable in the present study. 2 Furthermore, the rate of sudden death in hemodialysis patients was remarkably high (9.3% at 1 year and 24.7% at 5 years) in the present study. The 5-year rate of sudden death was much higher than 10.5% at 4 years after percutaneous coronary intervention reported in Japanese hemodialysis patients.
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AVR is the only definitive treatment in patients with severe AS. In the present study, the initial AVR strategy as compared with the conservative strategy was associated with a significantly lower long-term mortality rate in hemodialysis patients as well as in nonhemodialysis patients. A dramatically lower risk for sudden death in the initial AVR group would have been one of the major contributors for the lower long-term mortality in hemodialysis patients with severe AS. Furthermore, markedly lower risk for HF hospitalization in the initial Number of patients with at least 1 event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5 years. Follow-up was commenced on the day of surgical AVR or TAVI. AVR indicates aortic valve replacement; HR, hazard ratio; TAVI, transcatheter aortic valve implantation.
AVR strategy might also have contributed to the lower longterm mortality in hemodialysis patients with severe AS. On the other hand, it should be noted that the long-term mortality rate of hemodialysis patients with severe AS is very high even after AVR as compared with that in nonhemodialysis patients. Thourani et al reported the 5-year mortality rate of 71.5% after AVR in 114 hemodialysis patients, which was comparable to 63.2% in 131 hemodialysis patients in the present study. 8 The effect size of the initial AVR strategy relative to the conservative strategy for all-cause death was smaller in hemodialysis patients than in nonhemodialysis patients, which could be explained by the extremely high rate of aortic valve procedure-related death in hemodialysis patients, predominantly occurring within 6 months of the AVR procedure. The major causes of aortic valve procedure-related death were infection and hemorrhage. When undergoing surgical AVR, hemodialysis patients are more likely to have an increased risk of perioperative infection and hemorrhage because of having higher preoperative morbidity, more concomitant diseases, and more severe atherosclerosis than nonhemodialysis patients, which may have increased postoperative mortality rates in hemodialysis patients. Therefore, reduction in the procedural mortality of AVR is essential to improve the overall mortality outcome of hemodialysis patients with severe AS. In this context, less invasive TAVI might be an attractive alternative to surgical AVR in hemodialysis patients with severe AS. Currently, there are only a few small studies reporting outcomes of TAVI in hemodialysis patients; reported 30-day mortality rates included 14.0% (6/43) (transfemoral: 6.5%, and nontransfemoral: 33.3%) by Szerlip et al, 15 .2% (5/33) by Dumonteil et al, and 0% (0/17) by Maeda et al. [16] [17] [18] Further investigation on the role of TAVI in hemodialysis patients with severe AS is urgently needed.
Study Limitations
The present study has several limitations. First, its observational study design was prone to inherent bias. Particularly, the comparison between the initial AVR and conservative strategies would have been influenced by selection bias toward choosing less morbid patients in the initial AVR strategy. Also, the conservative group is a heterogeneous population and includes those with indications for surgery who were thought to be too risky and those not meeting indications for AVR because they were without symptoms. This could be noted as the Society of Thoracic Surgeons predicted risk of mortality is higher in the conservative group, yet the mean aortic pressure gradient is lower in this group. Despite an extensive multivariable adjustment, we could not Log-rank P<0.001
Years after surgical AVR/TAVI deny the possibility of unmeasured confounders and selection bias. Also, we did not take the competing risk of death into account for the nonfatal outcomes and also the competing risks of various causes of death. Secondly, we did not evaluate the influence of the duration after introduction of hemodialysis on long-term outcomes. Thirdly, the threshold to choose the AVR strategy and procedural outcomes of AVR might be different across the participating centers in this multicenter registry. Finally, the number of patients undergoing TAVI in our study was too small to clarify prognosis of hemodialysis patients undergoing TAVI.
Conclusions
Among hemodialysis patients with severe AS, the initial AVR strategy as compared with the conservative strategy was associated with significantly lower long-term mortality risk, particularly the risk for sudden death, although the effect size for the survival benefit of the initial AVR strategy was smaller than that in the nonhemodialysis patients.
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Definitions of the clinical events
Death was regarded as having its origin in cardiovascular unless obvious noncardiovascular causes were identified. Sudden death was defined as unexplained death of stable patients. Any death during hospitalization for aortic valve replacement or transcatheter aortic valve implantation was regarded as aortic valve procedure-related death. Aortic valve-related death included aortic valve procedure death, sudden death, and death due to heart failure related to aortic stenosis. Heart failure hospitalization was defined as hospitalization due to worsening heart failure requiring intravenous drug therapy. Myocardial infarction during the follow-up period was defined in accordance with the universal myocardial infarction guidelines. 1 Stroke was defined as ischemic or hemorrhagic stroke either requiring or prolonging hospitalization with symptoms lasting >24 hours. Life-threatening/disabling or major bleeding was defined as Bleeding Academic Research Consortium (BARC) classifications type 5, 3c, 3b, or 3a. Values are number (%), mean ± SD, or median (interquartile range) unless otherwise stated.
* Potential independent variables selected in the Cox proportional hazard models for all-cause death, cardiovascular death and a composite of aortic valverelated death or hospitalization for heart failure. † Potential independent variables selected in the Cox proportional hazard models for aortic valve-related death, aortic valve-procedure death, sudden death, non-cardiovascular death and hospitalization for heart failure. ‡ Body mass index was calculated as weight in kilograms divided by height in meters squared. § Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dl in women and <13.0 g/dl in men).
AVR=aortic valve replacement, STS=Society of Thoracic Surgeons, and PROM=predicted risk of mortality. Values are number (%), mean ± SD, or median (interquartile range) unless otherwise stated.
* Potential independent variables selected in the Cox proportional hazard models for all-cause death, cardiovascular death and a composite of aortic valverelated death or hospitalization for heart failure. † Potential independent variables selected in the Cox proportional hazard models for aortic valve-related death, aortic valve-procedure death, noncardiovascular death and hospitalization for heart failure. ‡ Body mass index was calculated as weight in kilograms divided by height in meters squared. § Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dl in women and <13.0 g/dl in men).
* Potential independent variables relevant to the choice of initial AVR selected for logistic regression model to develop propensity-score for the choice of initial AVR. † Body mass index was calculated as weight in kilograms divided by height in meters squared. ‡ Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dl in women and <13.0 g/dl in men).
AVR=aortic valve replacement, STS=Society of Thoracic Surgeons, and PROM=predicted risk of mortality. Number of patients with at least one event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5-year.
Follow-up was commenced on the day of the index echocardiography.
CI=confidence interval, and HR = hazard ratio. Number of patients with at least one event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5-year.
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In the initial AVR group, 1174 of 1197 patients actually underwent surgical AVR or TAVI. In the 1174 patients, TAVI was performed only in 11 non-dialysis patients, who were included in this Table. Regarding the prosthetic valve types, we did not have information in 20 patients who were operated on in hospitals other than the study participating centers.
AVR=aortic valve replacement, and TAVI=transcatheter aortic valve implantation Figure S1 . Cumulative incidence of surgical AVR or TAVI in the conservative group: dialysis versus non-dialysis patients.
